Servier acquires Symphogen to pick up oncology pipeline 07-Apr-2020 By Ben Hargreaves Servier buy outs its former partner to bolster its antibody discovery and development capabilities within oncology.
NEWS IN BRIEF Selexis and Symphogen expand partnership to progress two mAbs 11-Jul-2018 By Ben Hargreaves Selexis and Symphogen have announced that the latter has submitted INDs for clinical programmes to progress two mAbs using Selexis’ platform.
